Circulating Tumor DNA to Monitor Response to Neoadjuvant Chemotherapy in Breast Cancer
Recruiting
- Conditions
- Breast Cancer
- Registration Number
- NCT03260192
- Brief Summary
Investigators aim to investigate whether circulating tumor DNA is a sensitive marker to evaluate patients' response to neoadjuvant chemotherapy
- Detailed Description
Neoadjuvant chemotherapy(NAC) is traditionally for locally advanced disease, converting an inoperable to a resectable tumor.In recent years, it has become an option for patients of lower tumor stage to increase the possibility of breast conserving therapy. An effective method to monitor the response to NAC is important.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- Female
- Target Recruitment
- 150
Inclusion Criteria
- Female patients undergoing NAC
- Age: 18-70 yrs
- Any menopausal status
- Any hormal receptor status
Exclusion Criteria
- Metastasis discovered during NAC
- Lost more than 2 blood samples during NAC and surgery
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method death of breast cancer Follow-up time is estimated to be up to 5 years. The duration is from the date of diagnosis to date of death of breast cancer or date of death of any cause, whichever come first. The event is defined as death of breast cancer, which is a separate measure
- Secondary Outcome Measures
Name Time Method tumor recurrence or distant metastasis Follow-up time is estimated to be up to 5 years.The duration is from diagnosis to local recurrence or distant metastasis of breast cancer. Patients were followed up every six months in first three years, then followed up once a year. The event is defined as breast cancer local recurrence or distant metastasis
Trial Locations
- Locations (1)
Sunyat-sen Memorial Hospital
🇨🇳Guandong, Guangdong, China